[Immunotherapy of head and neck cancer. Current developments]

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Head and neck squamous cell cancer (HNSCC) requires improved therapeutic strategies to enhance patient prognosis.
• Current immunotherapy approaches face challenges due to pronounced immunosuppressive mechanisms and suppressed effector cells in HNSCC patients.

Purpose of the Study:

• To explore the potential of immunotherapy as a novel therapeutic strategy for HNSCC.
• To investigate how immunotherapy can overcome immunosuppression and restore antitumor immune responses in HNSCC.

Main Methods:

• Review of current anti-tumor immunotherapies, including unspecific immune stimulation, genetic modification, monoclonal antibodies (e.g., cetuximab), adoptive cell transfer, and tumor vaccination.
• Analysis of the role of tumor-specific antigens in targeted oncologic therapy.

Main Results:

• Immunotherapy holds promise for inducing antitumor immune responses by restoring suppressed effector cell populations.
• Various immunotherapy modalities exist, offering potential for targeted cancer treatment.

Conclusions:

• Biologic therapies, including immunotherapies, alone or in combination with conventional treatments, represent a promising future therapeutic option for HNSCC.
• Further research into immunotherapy is crucial for improving the clinical outcomes of HNSCC patients.